Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
暂无分享,去创建一个
E. Hirsch | A. Hartmann | R. Dodel | Lixia Lu | T. Lescot | S. Hunot | P. Michel | M. Breloer | C. Depboylu | A. Osterloh | C. Noelker | C. Henze | L. Morel | D. Skrzydelski | D. Alvarez-Fischer | Lydie J. Morel
[1] F. Cicchetti,et al. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration , 2011, Journal of Neuroinflammation.
[2] F. Cicchetti,et al. The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity , 2011, Brain, Behavior, and Immunity.
[3] W. Poewe,et al. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. , 2011, The American journal of pathology.
[4] W. Oertel,et al. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease , 2011, Journal of Neuroimmunology.
[5] S. Chasovskikh,et al. α-Synuclein Alters Toll-Like Receptor Expression , 2011, Front. Neurosci..
[6] E. Hirsch,et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism , 2011, Proceedings of the National Academy of Sciences.
[7] Andrew E. Parker,et al. Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.
[8] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[9] C. Kendziorski,et al. Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in female C3H/HeJ mice. , 2009, The Journal of infectious diseases.
[10] E. Hirsch,et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.
[11] E. Hirsch,et al. Modelling Parkinson‐like neurodegeneration via osmotic minipump delivery of MPTP and probenecid , 2008, Journal of neurochemistry.
[12] W. Rostène,et al. The chemokine stromal cell‐derived factor‐1/CXCL12 activates the nigrostriatal dopamine system , 2007, Journal of neurochemistry.
[13] R. Coffman,et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.
[14] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[15] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[16] S. Rivest,et al. Toll‐like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram‐negative bacterial cell wall components , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] Richard J Smeyne,et al. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus , 1999, Brain Research.
[18] P. Ricciardi-Castagnoli,et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.
[19] Acknowledgements , 1992, Experimental Gerontology.
[20] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[21] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[22] K. Maguire-Zeiss,et al. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. , 2012, Parkinsonism & related disorders.
[23] G. Nicolardi,et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. , 2008, Immunopharmacology and immunotoxicology.
[24] K. Yueh,et al. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females. , 2006, Parkinsonism & related disorders.